Holen Sie sich die Stockscreener-App
6.86
6.28%
-0.46
Handel nachbörslich:
6.86
Schlusskurs vom Vortag:
$7.32
Offen:
$7.15
24-Stunden-Volumen:
9.81M
Relative Volume:
2.28
Marktkapitalisierung:
$1.44B
Einnahmen:
$557.51M
Nettoeinkommen (Verlust:
$-35.71M
KGV:
-38.11
EPS:
-0.18
Netto-Cashflow:
$15.50M
1W Leistung:
-6.16%
1M Leistung:
-4.06%
6M Leistung:
-23.18%
1J Leistung:
-18.62%
1-Tages-Spanne:
$6.75
$7.26
1-Wochen-Bereich:
$6.75
$7.47
52-Wochen-Spanne:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
6.86 | 1.54B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-15 | Fortgesetzt | TD Cowen | Buy |
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Highlights: Strong Orladeo Growth and ... - Yahoo! Finance Canada
BioCryst Pharmaceuticals, Inc. Appoints Ron Dullinger as Chief Commercial Officer, Effective January 1, 2026 - MarketScreener
BioCryst Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2025 - MarketScreener
BioCryst Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
BioCryst (BCRX) Q3 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: BioCryst Q3 2025 earnings beat estimates, stock dips - Investing.com
BioCryst Pharmaceuticals (BCRX) Reports Strong Q3 Earnings, Rais - GuruFocus
BioCryst Reports Q3 2025 Financial Growth and Strategy - TipRanks
BioCryst (BCRX) Revenue Falls Short but Strategic Moves Drive Fu - GuruFocus
BioCryst (BCRX) Adjusts 2025 Financial Projections for ORLADEYO - GuruFocus
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q3 Revenue $159.4M, vs. FactSet Est of $163.0M - MarketScreener
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Posts Q3 Adjusted EPS $0.16 per Share, vs. FactSet Est of $0.07 - MarketScreener
BioCryst: Q3 Earnings Snapshot - Bluefield Daily Telegraph
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update - Bluefield Daily Telegraph
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyQuarterly Growth Report & AI Powered Market Entry Ideas - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolution2025 Top Decliners & Consistent Return Investment Signals - newser.com
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Volatility Report & Technical Entry and Exit Tips - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investors2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Y Intercept Hong Kong Ltd Increases Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackJobs Report & Daily Entry Point Trade Alerts - newser.com
# BioCryst’s SWOT analysis: stock positioned for growth amid HAE market expansion - Investing.com
BioCryst Pharmaceuticals (BCRX) Price Target Increased by 19.59% to 21.51 - Nasdaq
BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Why BioCryst Shares Plunged - AOL.com
Aug Shorts: Why hedge funds are buying BioCryst Pharmaceuticals Inc. stockTrade Entry Report & Weekly Stock Performance Updates - Fundação Cultural do Pará
When is the best time to exit BioCryst Pharmaceuticals Inc.July 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - newser.com
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.35%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):